Mammen P. Mammen
Keine laufenden Positionen mehr
Karriereverlauf von Mammen P. Mammen
Ehemalige bekannte Positionen von Mammen P. Mammen
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 25.06.2020 | 01.01.2022 |
| Walter Reed Army Institute of Research | Corporate Officer/Principal | - | - |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2017 | - |
| Corporate Officer/Principal | 07.11.2012 | 01.05.2017 |
Ausbildung von Mammen P. Mammen
| The Pennsylvania State University | Doctorate Degree |
| Williams College | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
Operativ
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| INOVIO PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
| Walter Reed Army Institute of Research |
- Börse
- Insiders
- Mammen P. Mammen
- Erfahrung
